MARKET WIREInvesting.com • 3h ago
Coya Therapeutics stock reiterated at Buy by H.C. Wainwright on trial enrollmentInvesting.com report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
Why COYA Stock dropped -9.30% Today — RQD Quant Desk Flash
$3.61 -9.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.54
Coya Therapeutics Inc. (COYA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $93.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on COYA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is COYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Coya Therapeutics Inc. (NASDAQ: COYA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.61 (-9.30% 1D, market cap $93.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, COYA ranks #684 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does COYA compare to RTSN and NTHI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COYA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RTSN (Retension Pharmaceuticals Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $93.2M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $92.9M). Among the 5-stock peer group, COYA leads on earnings multiple (N/A) while COYA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for COYA?
▼
Per COYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835022), Coya Therapeutics Inc. generated $7.9M in revenue (+123.6% YoY), -$21.2M in net income, and -$10.7M in free cash flow against $50.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.54 (-1.86%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COYA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY COYA SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (31% of score)
Altman Z-Score 6.08 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$4.95-14.1% Next Q
43
Q2 (-2Q)Grade D$4.25-7.3% Next Q
40
Q3 (-1Q)Grade E$3.94-8.4% Next Q
38
CurrentGrade D-$3.61-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a COYA Turnaround Squeeze
While COYA currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.61) and Max Pain ($3.79) forces dealer call-delta covering toward $6.95.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $COYA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “COYA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why COYA Stock dropped -9.30% Today — RQD Quant Desk Flash
Coya Therapeutics Inc. (COYA) dropped -9.30% to $3.61, trading at 2% of its 52-week range ($3.59 – $6.62). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($3.59 – $6.62) with RSI-14 at 27.5 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.61 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live COYA Headlines & Catalysts
MARKET WIREYahoo Finance • 6h ago
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS MeetingYahoo Finance report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 9h ago
Coya Therapeutics, Inc. Estimates – NASDAQ:COYATradingView report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 12h ago
ALS development takes priority as Coya Therapeutics (COYA) delays another trial's planned start.Stock Titan report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBusiness Wire • 15h ago
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSBusiness Wire report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBusiness Wire • 18h ago
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare ConferenceBusiness Wire report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBusiness Wire • 21h ago
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALSBusiness Wire report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 5d ago
Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS TreatmentALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes implementation of a prospective
MARKET WIREBenzinga • 19d ago
Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral SclerosisOLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash runway guidance remains
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COYA)
- ✓Walkthrough of COYA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
COYA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.66%▼ DESCENDING CHANNEL
2026-10-30O $3.96H $4.09L $3.59C $3.61VOL 214.3K
RES: $4.93SUP: $3.01SMA50: $4.61SMA200: $4.64
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
COYA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +123.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on COYA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for COYA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for COYA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COYA)
Health Care Rank #684 of 1016
⚔️ RTSN vs COYA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (COYA vs. RTSN, NTHI, PLYX, GNLX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Coya Therapeutics Inc. (COYA) ranks #684 by composite RQD confidence (35/100, grade D-) and #670 by equity capitalization ($93.4M). Within this direct 5-issuer industry benchmark cohort, COYA leads on earnings valuation at N/A trailing P/E, while COYA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with COYA at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COYA
ACTIVE
Coya Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -9.30% | $93.4M | Benchmark Subject |
| RTSN Retension Pharmaceuticals Inc. | D | 48/100 | — | — | — | -3.97% | $93.2M | /rtsn-vs-coya → |
| NTHI NeOnc Technologies Holdings Inc. | E | 33/100 | — | — | -35.0% | +4.49% | $92.9M | /nthi-vs-coya → |
| PLYX Polaryx Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -5.91% | $92.7M | /plyx-vs-coya → |
| GNLX Genelux Corporation | E | 29/100 | — | — | -35.0% | -0.95% | $95.0M | /gnlx-vs-coya → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001835022In its most recent audited fiscal period (FY2025, filed 2025-12-31), Coya Therapeutics Inc. (COYA) reported GAAP revenue of $7.9M (+123.6% vs. FY2024 revenue of $3.6M , and +32.4% cumulative change since FY2023) , GAAP net income of -$21.2M, operating cash flow of -$10.7M, and free cash flow of -$10.7M (-4.4% YoY). On the balance sheet, COYA closed FY2025 with $50.0M in total assets against $0 in total debt (Altman Z-Score: 6.08, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $7.9M | -$21.2M | -$10.7M | -$10.7M | $50.0M | — |
| FY2024 (FY) | 2024-12-31 | $3.6M | -$14.9M | -$10.3M | -$10.3M | $44.3M | — |
| FY2023 (FY) | 2023-12-31 | $6.0M | -$8.0M | -$11.2M | -$11.2M | — | — |
3. COYA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs COYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Coya Therapeutics Inc. (NASDAQ: COYA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.61 (-9.30% 1D, market cap $93.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, COYA ranks #684 in composite RQD confidence.
How does COYA compare to RTSN and NTHI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COYA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RTSN (Retension Pharmaceuticals Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $93.2M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $92.9M). Among the 5-stock peer group, COYA leads on earnings multiple (N/A) while COYA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for COYA?
Per COYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835022), Coya Therapeutics Inc. generated $7.9M in revenue (+123.6% YoY), -$21.2M in net income, and -$10.7M in free cash flow against $50.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is COYA trading relative to its 50-day, 200-day, and 52-week technical levels?
COYA last traded at $3.61 (-9.30% on volume of 214,748 shares), positioning the stock -21.69% below its 50-day simple moving average ($4.61) and -22.20% below its 200-day simple moving average ($4.64). Across its 52-week range of $3.59 to $6.62, COYA sits at the 0.7% percentile with a 14-day RSI of 27.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.16 to $4.06).
COYA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is COYA stock moving today?
Why COYA Stock dropped -9.30% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 35/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
COYA — Coya Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:44:21Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, COYA scores 35 out of 100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:
- Fundamental Cash Engine (9 / 20): Per the RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -11.5%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow that would support the equity value on an earnings basis.
- Whale 13F Flow (6 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The score is below the midpoint, so the institutional signal is weak rather than supportive.
- Insider Conviction (3 / 20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider conviction signals in the source data.
- Macro Regime Fit (6 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity noted. Market-level moves are expected to pass through roughly one-for-one, with no offsetting macro advantage identified.
- Forensic Balance Sheet (11 / 20): Per the RQD rating, Altman Z is 6.08, Piotroski F is 3/9, and Debt/Equity is 0.5. The Altman Z reading is strong, but the Piotroski F reading is weak, so the balance sheet supports near-term solvency more than improving operating quality.
Net implication for a prospective investor: the upside case depends on a turnaround in cash generation that the source data does not yet show, while the downside is shaped by negative operating and net margins and a share price that has fallen 9.3% on the reporting date. The data describes a high-risk, pre-profit profile; it does not establish a valuation.
Business
Coya Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, its market capitalization is $0.1B. Per the financials, it reported revenue of $7.9M in FY 2025, indicating some commercial or collaborative revenue base. Not available in source data: product lines, customer categories, and specific revenue model details.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $7.9M | $-22.6M | $-21.2M | N/A | $-10.7M | $46.8M | N/A |
| FY 2024 | $3.6M | $-17.2M | $-14.9M | N/A | $-10.3M | $38.3M | N/A |
| FY 2023 | $6.0M | $-7.9M | $-8.0M | N/A | $-11.2M | N/A | N/A |
Per the SEC financials, operating and net margins are both -60% and gross margin is 0%. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 6.08 and the Piotroski F-Score is 3/9. Per the RQD rating, Debt/Equity is 0.5, and FY 2025 reported cash of $46.8M against net losses of $-21.2M.
Recent Catalysts & News Wire Analysis
- Positive/neutral market wire: An H.C. Wainwright Buy reiteration tied to trial enrollment (per Investing.com) and a Business Wire announcement of full enrollment in the Phase 2/3 ALSTARS trial of COYA 302 for ALS are the main constructive items. A Business Wire notice of participation at Chardan's 10th Annual Healthcare Conference and a Yahoo Finance item on NfL biomarker stratification for the ALSTARS trial, to be presented at the 2026 NEALS meeting, are also in the feed.
- Risk Watch (RED): A Stock Titan report states that ALS development takes priority as COYA delays another trial's planned start, flagged RED in the news feed.
- Proprietary signals: Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE and no butterfly links are present. Upstream and downstream dependencies cannot be mapped from the source data. The sector correlation is limited to Health Care and the Biotechnology: Pharmaceutical Preparations industry. The 2nd-order item to watch is trial-timing risk: the RED-flagged delay in another trial's start shows that pipeline sequencing, rather than a supply chain, is the more visible ripple channel in the source material.
Open Questions
- What is the cash runway implied by the FY 2025 cash balance of $46.8M against the FY 2025 FCF of $-10.7M, and how does it compare with the trial timelines in the news feed?
- Which specific trial was delayed, and what is the revised start date referenced in the Stock Titan report?
- What are the debt terms behind the Debt/Equity of 0.5, given that the debt line is N/A in the financial table?
- What drove the revenue movement from $3.6M in FY 2024 to $7.9M in FY 2025, and is that revenue recurring?
- What are the EPS and P/E figures on a TTM basis, given that EPS is N/A across all reported periods?
COYA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Coya Therapeutics Inc. (COYA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Investing.com • 3h ago
Coya Therapeutics stock reiterated at Buy by H.C. Wainwright on trial enrollment Investing.com report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 6h ago
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting Yahoo Finance report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 9h ago
Coya Therapeutics, Inc. Estimates – NASDAQ:COYA TradingView report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 12h ago
ALS development takes priority as Coya Therapeutics (COYA) delays another trial's planned start. Stock Titan report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Business Wire • 15h ago
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS Business Wire report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Business Wire • 18h ago
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference Business Wire report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Business Wire • 21h ago
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS Business Wire report covering Coya Therapeutics Inc. (COYA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 5d ago
Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes implementation of a prospective
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
COYA Bull vs. Bear Conversation Board — What's Your Call at $3.61?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON COYA 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $3.18 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is COYA (D- • RQD 35/100) a Buy at $3.61?
Welcome to the COYA (Coya Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $3.00 (-16.9%)
Spot @ $3.61 Pump the brakes on COYA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on COYA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Coya Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $4.33 (+19.9%)
Spot @ $3.61 COYA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on COYA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.61 (52-wk range $3.59 - $6.62), any beat on forward guidance forces shorts and underweight funds to chase.